BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Subscribe to Biopharm Executive!

  Get market insights, deals, business stories and deep dives into key policy issues impacting biopharma. Expect us in your inbox every Wednesday.

  July 19, 2024
• Subscribe to GenePool!

  Get top headlines and the most important breaking stories in biopharma. Expect us in your inbox Monday to Friday.

  July 19, 2024
• Subscribe to ClinicaSpace!

  Get clinical trial results, research news, the latest in cancer, cell and gene therapy and deep dives into key issues in drug discovery and development. Expect us in your inbox every Monday.

  July 19, 2024
• Subscribe to Career Insider!

  Get expert career advice, insights on job trends and quarterly biopharma job market reports. Expect us in your inbox every Thursday.

  July 19, 2024
• 

  Grant Playter

  Grant Playter is a professional freelance writer in the biopharma field, with a particular focus on investment and market trends. Connect with Grant on LinkedIn or reach out directly to grantplayter@gmail.com.
• 

  Career Advice

  2024 Job Search Toolkit

  BioSpace has updated our Job Search Toolkit, including recent resources to help you succeed with your next job search.

  July 19, 2024

   · 

  3 min read

   · 

  BioSpace Editorial Staff
• 

  Kidney Cancer

  AVEO’s Fotivda Combo Flunks Phase III Renal Cell Carcinoma Study

  While its investigational regimen fell short of the primary efficacy endpoint, AVEO dug into data from its control group and touted a “clinically meaningful” improvement in progression-free survival in patients receiving Fotivda monotherapy.

  July 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Series B

  George Church Startup Nets $60M to Take Non-Standard Amino Acids to the Clinic

  GRO Biosciences will use the Series B funds to launch a Phase I trial for ProGly-Uricase, its investigational therapy for gout.

  July 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Biosimilars

  Boehringer Ingelheim Partners With GoodRx to Offer Humira Biosimilar at 92% Discount

  In a bid to take advantage of Humira’s slow loss of market share, Boehringer Ingelheim is offering its biosimilar at a 92% discount exclusively to patients who buy the product on GoodRx.

  July 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Updated: Artiva’s IPO Jumps to $167M

  Cell therapy biotech Artiva Biotherapeutics plans to use the funds raised to support the development of its AlloNK therapy for systemic lupus erythematosus.

  July 19, 2024

   · 

  2 min read

   · 

  Tyler Patchen